Interested parties with appropriate projects should contact the company
Debiopharm Group, a Switzerland-based global biopharmaceutical group, aims to expand activities at Debiopharm Research & Manufacturing, its industrial development and production facility in Martigny, through the purchase of industrial high-value added activities or companies in the pharmaceutical, biotech or medtech field.
The Group of four companies is active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments.
Debiopharm Research & Manufacturing has 35 years of expertise in drug development including chemical synthesis, formulation improvement and manufacturing. Major investments have been made since 2007 to automate the facility and increase its industrial capacity.
The objective now is to expand industrial operations in Martigny and generate a 'double-digit million' revenue annually.
The company says expertise in R&D and manufacturing of hard-to-make pharmaceutical products, modern infrastructure combined with high-tech GMP-compliant production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe, are some of the features that will enable this objective to be met.
'We want to be the bridge between development and industrialisation and supply Swiss-made products manufactured using state-of-the-art technology,' says Cédric Sager, Chief Executive of Debiopharm Research & Manufacturing. 'Hard-to-make drugs, highly complex formulated drugs, biologic niche products, premium diagnostics and medical devices are on our wish-list.'
Thierry Mauvernay, Delegate of the Board of Debiopharm Group, explains that the company has invested heavily during the last few years to automate the Martigny site. 'Thanks to our efforts, we have increased our productivity,' he said. 'Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development.'
Interested parties with appropriate projects are invited to contact Sandya von der Weid at Debiopharm at email@example.com.
To be considered projects must be close to commercialisation with realistic prospects of achieving targeted annual revenues within the next few years.